Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China.

ABSTRACT:

Background

Rilertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated a favorable efficacy and safety profile in adult patients with EGFR T790M + advanced NSCLC. This study examined the cost-effectiveness of rilertinib compared with osimertinib in the second-line treatment for EGFR T790M mutation-positive advanced NSCLC in the Chinese healthcare setting.

Methods

A Markov model was developed to project economic and health outcomes. An unanchored matching-adjusted indirect comparison (MAIC) was used to compare the efficacy of rilertinib with osimertinib. Cost and utility values were obtained from Chinese health system data, public databases, and the published literature. Model robustness was assessed through determi

SUBMITTER: Li X 

PROVIDER: S-EPMC12545111 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature